Skip to main content

Mechanism of Action

Important Safety Information

WARNINGS AND PRECAUTIONS

  • Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer...

Indication

LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
References: 1. Advanced Accelerator Applications receives FDA approval for Lutathera® for treatment of gastroenteropancreatic neuroendocrine tumors [news release]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 26, 2018. Accessed April 15, 2022. https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutathera-treatment-gastroenteropancreatic-neuroendocrine-tumors 2. Zamora V, Cabanne A, Salanova R, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 2010;42(3):220-225. 3. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp.